معرفی
Matthew Lloyd is a Senior Lecturer in the Department of Life Sciences at the University of Bath, where he conducts research at the intersection of chemical biology, enzymology, and drug discovery. His work focuses on enzyme targets in cancer and infectious diseases, particularly alpha-methylacyl-CoA racemase (AMACR) in prostate cancer and tuberculosis. He collaborates with leading researchers including Professor K. Ravi Acharya, Professor Mike Threadgill, and Professor Tony James across disciplines to develop novel therapeutics.
- PhD in Clavulanic Acid Biosynthesis, University of Oxford (1989–1992)
- BSc in Biological Chemistry, University of Leicester (1986–1989)
His research interests lie in chemical biology approaches to cancer, with a focus on enzyme mechanisms, inhibitor development, and high-throughput screening. He investigates AMACR’s role in fatty acid metabolism and ibuprofen activation, aiming to develop both therapeutic inhibitors and diagnostic assays. His work also extends to targeting tankyrases and developing delivery systems for potent anticancer drugs.
The recent publications highlight a strong trend in enzymology and pharmacological methodology, particularly in enzyme kinetics, structural characterization of AMACR, and rigorous analysis of dose-response curves for accurate IC50/EC50 determination. His work bridges fundamental biochemistry with translational drug discovery.
- Fellow of the Royal Society of Biology (FRSB) (2018–2021)
- Editorial Board Member, The Biochemist, Biochemical Society (from 2017)
- Member, Biochemical Society (from 1990)
Matthew Lloyd actively supervises doctoral students and leads or co-leads multiple research projects funded by Prostate Cancer UK and the World Cancer Research Fund. He has been Principal Investigator on projects such as 'AMACR Targeted Drugs for Treating Advanced Prostate Cancer' and 'Refinement of a Polymeric System Delivering CGIs to Prostate Tumours'. His collaborative network includes experts in chemistry, life sciences, and cancer biology, reflecting a multidisciplinary approach. He regularly presents at academic events, including the European Society of Applied Biocatalysis webinar and the Chris J. Schofield Symposium.
His research is conducted within a collaborative team environment involving Dr. Tim Woodman, Professor Mike Threadgill, and Dr. Andy Thompson, focusing on enzyme-targeted therapies and drug delivery systems for cancer treatment.
